Merck to unveil Phase 3 melanoma, endometrial and lung cancer data at ESMO 2026
Merck (MRK) will present first‑time Phase 3 results from three pivotal trials at the European Society for Medical Oncology Congress in October 2026. INTerpath‑001 will show the mRNA‑based intismeran autogene plus pembrolizumab in resected stage IIB‑IV melanoma, TroFuse‑005 will report sacituzumab tirumotecan versus chemotherapy in advanced or recurrent endometrial cancer, and KEYNOTE‑C93 will compare pembrolizumab monotherapy with carboplatin‑paclitaxel in dMMR endometrial cancer. The company will also host an Oncology Investor Event on 26 October.
Why it matters
Merck says the data demonstrate the strength and depth of its oncology portfolio and will allow investors to gauge the commercial potential of the new mRNA neoantigen therapy and TROP2‑directed ADC. The investor event will provide senior management an opportunity to update the market on the strategy and pipeline.
Key facts
- 1Merck will present data from the INTerpath‑001 trial in a Presidential Symposium on 24 October 2026. oncodaily.com
- 2The TroFuse‑005 and KEYNOTE‑C93 trials will be presented in a Presidential Symposium on 26 October 2026. oncodaily.com
- 3More than 90 oncology abstracts covering over 20 tumor types will be shown at ESMO 2026. oncodaily.com
- 4Merck will hold an Oncology Investor Event on 26 October 2026 at 7:30 p.m. CET/2:30 p.m. ET. stocktitan.net
- 5INTerpath‑001 met its primary endpoint of recurrence‑free survival and its key secondary endpoint of distant metastasis‑free survival. oncodaily.com
- 6TroFuse‑005 met its primary endpoints of overall survival and progression‑free survival, and also achieved its key secondary endpoint of objective response rate. oncodaily.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.